Otamixaban: Difference between revisions

Jump to navigation Jump to search
m (Protected "Otamixaban": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
Line 27: Line 27:
{{CMG}}
{{CMG}}
__NOTOC__
__NOTOC__
{{Editor Help}}
 


==Overview==
==Overview==

Revision as of 14:36, 20 August 2012

Otamixaban
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC25H26N4O4
Molar mass446.498 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

Otamixaban (INN) is an inhibitor of Factor Xa,[1] currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

See also

References

  1. Guertin KR, Choi YM (2007). "The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development". Curr. Med. Chem. 14 (23): 2471–81. PMID 17979700.


Template:WikiDoc Sources